ARYA Sciences Acquisition Corp IV
Status: Deal Closed
U=S
| IPO Proceeds, $M | $149.50M |
|---|---|
| IPO Date | Feb 26, 2021 |
| CEO | Adam Stone |
| Left Lead | Goldman Sachs |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 + 12 + 12 |
| IPO Sector |
Healthcare
Life sciences and medical technology in North America and Europe |
| IPO Geography | Global |
| Target Company | Adagio Medical |
| Deal Announced | Feb 14, 2024 |
| Deal Size, $M | $116.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Jul 26, 2024 |
| Amendment Vote | Feb 27, 2024 |
| Closing Date | Jul 31, 2024 |
Formerly ARYD
ADGM
| Price | $1.89 |
|---|---|
| Last closing price | $2.44 |
| H/L, today | $1.69 / $2.64 |
| Volume, today | 243,574 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on ARYA Sciences Acquisition Corp IV:
- Structure and cap table
- 7 directors & officers
- 45 filings and events
- 2 underwriters
- 2 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Joseph Edelman | 65 | Chairman |
| Adam Stone | 41 | Chief Executive Officer and Director |
| Michael Altman | 39 | Chief Financial Officer and Director |
| Konstantin Poukalov | 37 | Chief Business Officer |
| Todd Wider | 56 | Director |
| Leslie Trigg | 50 | Director |
| Michael Henderson | 31 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Goldman Sachs | Joint BR | 6,500,000 | units |
| Jefferies | Joint BR | 6,500,000 | |
| 13,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.